Status:
UNKNOWN
Establishment of MRI Model for pTRG in Rectal Cancer With Establishment of
Lead Sponsor:
Peking University Cancer Hospital & Institute
Collaborating Sponsors:
Capital's Funds for Health Improvement and Research (2020-1- 2151).
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study proposeto integrate a variety of imaging quantitative indicators to establish a new MRI-based tumor response regression(mrTRG) classification method. The accuracy of the established mrTRG c...
Detailed Description
The study included two part: one is a retrospective single-center cohort for analyzing quantitative MRI factors associated with pTRG, from which a new MRI-based tumor response regression(mrTRG) classi...
Eligibility Criteria
Inclusion
- biopsy-proved primary rectal cancer
- baseline MRI confirmed LARC (cT3 and/or cN+)
- scheduled to take neoadjuvant therapy
- receive baseline and preoperative pelvic MRI
- receive TME surgery after NAT
- have routine follow-up after the operation
Exclusion
- history of malignancy or multiple primary cancers
- receive surgery directly without NAT
- don't receive TME surgery
- don't complete NAT
- simultaneous distant metastasis at the baseline diagnosis
- lack of baseline or preoperative pelvic MRI
- incomplete or unavailable pathological information
- lost to follow-up within three months after surgery (lost since the first follow-up visit)
Key Trial Info
Start Date :
May 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
385 Patients enrolled
Trial Details
Trial ID
NCT05374044
Start Date
May 18 2020
End Date
December 31 2025
Last Update
June 22 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100039
2
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
3
Peking University Shougang Hospital
Beijing, Beijing Municipality, China, 100142